significantDiagnostic advanceJune 1, 2019

Eurofever/PRINTO evidence-based classification criteria for TRAPS validated

TNF Receptor-Associated Periodic Syndrome →

Summary

Gattorno et al. (2019) published validated classification criteria for TRAPS within the Eurofever/PRINTO framework, incorporating genetic confirmation of pathogenic TNFRSF1A variants plus clinical features (duration of episodes >6 days, migratory rash, periorbital edema, myalgia). The criteria achieved 95% sensitivity and 97% specificity, enabling standardized diagnosis for clinical trials.

High-penetrance pathogenic variants. Disrupt disulfide bonds in CRD1/CRD2 of the TNFR1 extracellular domain. Associated with severe phenotype and high amyloidosis risk (24% vs 2% for non-cysteine).

TNFRSF1AT50M (p.Thr79Met)

Most common high-penetrance pathogenic variant. Affects a conserved hydrogen bond critical for protein folding in CRD1. Despite not disrupting a cysteine, carries high disease penetrance and amyloidosis risk similar to cysteine mutations.

TNFRSF1AR92Q (p.Arg121Gln)

Low-penetrance variant of uncertain pathogenic significance. Present in 1.2–4% of healthy Caucasians. Associated with milder disease, shorter episodes, less familial aggregation (19% vs 64%), and higher spontaneous resolution rates. Classified as INSAID Group B (uncertain significance).

TNFRSF1AP46L (p.Pro75Leu)

Another low-penetrance variant. Found at high frequency in sub-Saharan West African populations. Clinical significance debated — may be a benign polymorphism in some ethnic backgrounds.